The stock of Achaogen Inc (NASDAQ:AKAO) is a huge mover today! About 720,837 shares traded hands or 408.77% up from the average. Achaogen Inc (NASDAQ:AKAO) has risen 24.93% since February 26, 2016 and is uptrending. It has outperformed by 14.51% the S&P500.
The move comes after 8 months positive chart setup for the $132.14M company. It was reported on Oct, 1 by Barchart.com. We have $10.83 PT which if reached, will make NASDAQ:AKAO worth $167.82 million more.
Analysts await Achaogen Inc (NASDAQ:AKAO) to report earnings on November, 3. They expect $-0.43 EPS, up 10.42% or $0.05 from last year’s $-0.48 per share. After $-0.81 actual EPS reported by Achaogen Inc for the previous quarter, Wall Street now forecasts -46.91% EPS growth.
Achaogen Inc (NASDAQ:AKAO) Ratings Coverage
Out of 3 analysts covering Achaogen (NASDAQ:AKAO), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Achaogen has been the topic of 3 analyst reports since March 16, 2016 according to StockzIntelligence Inc. On Tuesday, June 14 the stock rating was upgraded by Wedbush to “Outperform”. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Hold” rating by Needham on Wednesday, March 16. Cowen & Co downgraded Achaogen Inc (NASDAQ:AKAO) on Thursday, March 31 to “Market Perform” rating.
According to Zacks Investment Research, “Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment decreased to 1.22 in 2016 Q2. Its down 0.47, from 1.69 in 2016Q1. The ratio worsened, as 8 funds sold all Achaogen Inc shares owned while 10 reduced positions. 10 funds bought stakes while 12 increased positions. They now own 13.87 million shares or 102.18% more from 6.86 million shares in 2016Q1.
Nea Com Ltd Llc owns 4.72 million shares or 0.93% of their US portfolio. Spark Investment Llc holds 0.01% or 15,100 shares in its portfolio. Moreover, Art Advsr Ltd Llc has 0.01% invested in Achaogen Inc (NASDAQ:AKAO) for 37,507 shares. Morgan Stanley holds 48,782 shares or 0% of its portfolio. Tfs Capital Ltd Liability Corporation owns 13,587 shares or 0.01% of their US portfolio. Nomura Hldg Inc holds 0% or 25,100 shares in its portfolio. Fincl Bank Of America De accumulated 0% or 32,700 shares. Bridgeway Mngmt has 0.01% invested in the company for 156,185 shares. Cqs Cayman Lp accumulated 90,850 shares or 0.03% of the stock. Fmr Lc owns 2.62 million shares or 0% of their US portfolio. Eagle Global Limited Com accumulated 38,749 shares or 0% of the stock. Putnam Ltd reported 123,527 shares or 0% of all its holdings. Baker Bros Advsrs L P holds 100,000 shares or 0% of its portfolio. Moreover, Jacobs Levy Equity has 0% invested in Achaogen Inc (NASDAQ:AKAO) for 62,572 shares. Ballentine Prtnrs accumulated 0.01% or 19,823 shares.
More recent Achaogen Inc (NASDAQ:AKAO) news were published by: Marketwatch.com which released: “Achaogen stock price target raised to $10 from $7 at Wedbush Securities” on July 14, 2011. Also Streetinsider.com published the news titled: “Form 4 Achaogen Inc For: Sep 23 Filed by: Sarpangal Zeryn” on September 28, 2016. Quotes.Wsj.com‘s news article titled: “Achaogen Inc. AKAO (US: Nasdaq)” with publication date: March 09, 2014 was also an interesting one.
AKAO Company Profile
Achaogen, Inc., incorporated on November 26, 2002, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections, which include a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. The Company’s development plan for plazomicin includes over two Phase III clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.